Bharat Immunolog — 360° view

Bharat Immunolog, a company in the Pharmaceuticals industry, reported revenue of ₹7.65 crore and a net loss of ₹3.88 crore for the March 2023 quarter.

Bharat Immunolog (BSE: BIBCL) closed at ₹9.00 on 20 Nov 2026, down 55.3% over the past year. Its market capitalisation is ₹39 crore.

Share price
₹9.00 (20 Nov 2026)
Market cap
₹39 Cr (20 Nov 2026)
Revenue
₹8 Cr (March 2023 quarter)
Net profit
₹-4 Cr (March 2023 quarter)
ROCE
-9.27% (FY23)
ROE
-17.7% (FY23)
Book value
₹18.2 (FY23)
Dividend yield
0.00% (FY23)
52-week high / low
₹22.61 / ₹7.11 (20 Nov 2026)
1-year return
-55.3% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BSE: BIBCL

Incorporated in 1989, Bharat Immunological and Biologicals Corporation Ltd manufactures biotechnology-based pharmaceuticals.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.